Evonile Pharma Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NOVARTIND.BO | WINDLAS.NS | IOLCP.NS | 000739.SZ | EVO | TEVA | |
|---|---|---|---|---|---|---|
| Market cap | 42.46B | 19.01B | 55.50B | 25.56B | 557.96M | 48.81B |
| P/E (TTM) | 43.4 | 29.5 | 27.3 | 31.5 | — | 97.3 |
| Forward P/E | — | — | 17.5 | 21.4 | -8.3 | 13.4 |
| Price/book | 5.2 | 3.3 | 2.9 | 3.9 | 0.7 | 6.1 |
| Dividend yield | — | 0.72% | 0.54% | 1.75% | — | — |
| 1-year change | +106.60% | −5.35% | +102.86% | +43.01% | −53.73% | +71.10% |
| Today | +0.09% | +5.47% | +2.89% | +2.22% | +1.29% | −0.14% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All NOVARTIND.BO news ›Evonile Pharma posts Rs 77.54 cr net loss in Q2
New Delhi, Nov 3 (PTI) Evonile Pharma, formerly Novartis India, on Tuesday reported a net loss of Rs 77.54 crore in the September quarter, dragged down by exceptional items. The pharma company posted a profit of Rs 24.22 crore in the…
Evonile Pharma Approves Fundraising of Up to Rs 900 Crore Through Rights Issue
Mumbai: Evonile Pharma Limited, formerly known as Novartis India Limited, has approved a proposal to raise funds of up to Rs 900 crore through a rights issue of partly paid-up equity shares. The company’s Board of Directors approved the…
Evonile Pharma Approves Fund Raising Via Partly Paid-Up Equity Shares For Up To 9 Billion Rupees
TradingView Evonile Pharma Approves Fund Raising Via Partly Paid-Up Equity Shares For Up To 9 Billion Rupees
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- medicaldialogues.in2
- news18.com2
- news.ventureintelligence.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.